Compositions and methods for the treatment of sepsis

Details Compositions and methods for the treatment of sepsis Compositions and methods for the treatment of sepsis

2006-01-17

2006-01-17

Chan, Christina (Department: 1644)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

8 to 10 amino acid residues in defined sequence

C530S329000, C530S330000, C424S185100, C424S278100

Reexamination Certificate

active

06987166

ABSTRACT:
The present invention relates to compositions and methods for the prevention and treatment of blood-borne and toxin mediated diseases, and in particular anti-C5a antibodies for the prevention and treatment of sepsis in humans as well as other animals. The present invention also relates to methods of generating anti-C5a antibodies employing C-terminal truncated C5a peptides.

REFERENCES:
patent: 4357272 (1982-11-01), Polson
patent: 5051448 (1991-09-01), Shashoua
patent: 5169862 (1992-12-01), Burke, Jr. et al.
patent: 5192746 (1993-03-01), Lobl et al.
patent: 5260203 (1993-11-01), Ladner et al.
patent: 5340923 (1994-08-01), Carroll
patent: 5539085 (1996-07-01), Bischoff et al.
patent: 5559103 (1996-09-01), Gaeta et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5576423 (1996-11-01), Aversa et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5658727 (1997-08-01), Barbas et al.
patent: 5904922 (1999-05-01), Carroll
patent: 0 245 993 (1987-11-01), None
patent: WO 96/39503 (1996-12-01), None
Chen et al. Journal of Biochemistry, 273(17):10411-19 (1998).
Merriam Webster's Collegiate Dictionary, Tenth Edition, 1996 p. 1305, column 1, lines 4-6.
Morgan, El et al. Identification and characterization of the effector region within human C5a responsible for stimulation of IL-6 synthesis. J. Immunol. (1992) 148(12): 3937-3942.
Ames et al., “Isolation of Neutralizing Anti-C5a Monoclonal Antibodies from a Filamentous Phage Monovalent Fab Display Library,”J. of Immunology152:4572-4581 (1994).
Bone, “The Pathogenesis of Sepsis,”Ann. Intern. Med. 115:457-469 (1991).
Caplan et al., “Infection Surveillance and Control in the Severely Traumatized Patient,”Am. J. Med. 70:638-640 (1981).
Caruthers et al., “New chemical methods for synthesizing polynucleotides,”Nuc. Acids Res. Symp. Ser. 7:215-233 (1980).
Chow and Kempe, “Synthesis of oligodeoxyribonucleotides on silica gel support,”Nuc. Acids Res. 9:2807-2817 (1981).
Crea and Horn, “Synthesis of oligonucleotides on cellulose by a phosphotriester methods,”Nuc. Acids Res. 9:2331 (1980).
Creighton (1983)Proteins Structures And Molecular Principles, W H Freeman and Co, New York N.Y..
Czermak et al., “Protective effects of C5a blockade in sepsis,”Nature5:788-792 (1999).
Elzaim, et al., “Generation of Neutralizing Antipeptide Antibodies to the Enzymatic Domain ofPseudomonas aeruginosaExotoxin A,”Infect. Immun. May;66(5):2170-9 (1998).
Evans et al., “An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies,”Nature339:385 (1989).
Gerard, C. et al., “Amino Acid Sequence of the Anaphylatoxin from the Fifth Component of Procine Complement,”J. Biol. Chem. 255(10), 4710-4715, (1980).
Gluzman, “SV40-Transformed Simian Cells Support the Replication of Early SV40 Mutants,”Cell23:175 [1981].
Hatherill et al., “Effects of Anti-C5a Antibodies on Human Polymorphonuclear Leukocyte Function: Chemotaxis, Chemiluminexcence, and Lysosomal Enzyme Release,”Journal of Biological Response Modifiers8:614-624 (1989).
Hill, J.H. and Ward, P.A., “The Phlogistic Role of C3 Leukotactic Fragments in Myocardial Infarcts of RatsI,”J. Exp. Med. 133:885-900, (1971).
Hochuli et al., “New Metal Chelate Adsorbent Selective For Proteins And Peptides Containing Neighbouring Histidine Residues,”J. Chromatography411:177 (1987).
Hoffman et al., “Prognostic Variables for Survival of Neonatal Foals Under Intensive Care,”J. Vet. Int. Med. 6:89-95 (1992).
Huang et al., “Vaccinia Virus Recombinants Expressing an 11-Kilodalton β-Galactosidase Fusion Protein Incorporate Active βGalactosidase in Virus Particles,”J. Virol. 62:3855 (1988).
Joklik et al. (eds.), “Streptococcus pneumoniae,”Zinsser Microbiology, 18th ed., p. 485, Appleton-Century-Crofts, Norwalk, CT (1984).
Kettleborough, et al., “Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation,”Protein Engineering, vol. 4, No. 7, pp 773-783 (1991).
Kohl, J., Bitter-Suermann, D.,Anaphylatoxins. Complement in health and disease., Edited by Whaley, K., Loos, M., Weiler, J.M., Kluwer Academic publishers, pp 299-324, (1993).
Kohler, G. and Milstein, C., “Continuous cultures of fused cells secreting antibody of predefined specificity,”Nature256:495 (1975).
Kola et al., “Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and site=directed mutagenesis,”Immunotechnology1:115-126 (1996).
Kozbor and Roder, “The production of monoclonal antibodies fromhuman lymphocytes,”Immunol. Today4:72-79 (1983).
Larrick et al., “Characterization of Murine Monoclonal Antibodies That Recognize Neutralizing epitopes on Human C5a,”Infection and Immunity55:1867-1872 (Aug. 1987).
Machiedo et al. “Patterns Of Mortality In a Surgical Inventive Care Unit,”Surg. Gyn&Obstet. 152:757-759 (1981).
Mandecki W, et al., “Chemical Synthesis of a gene encoding the human complement fragment C5a and its expression ofEscherichia coli,”Proc Natl Sci U S A. Jun;82(11):3543-7(1985).
Matteucci and Caruthers, “The Synthesis of Oligodeoxypyrimidines on a Polymer Support,”Tetrahedron Lett21:719 (1980).
Meek et al., “The Baltimore Sepsis Scale: Measurement of Sepsis in Patients with Burns Using a New Scoring System,”J. Burn Care Rehab. 12:564-568 (1991).
Mohr et al., “Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis,”European Journal of Clinical Investigation28:227-234 (1998).
Morris et al., “Endotoxemia in neonatal calves given antiserum to a mutantEscherichia coli(J-5),”Am. J. Vet. Res. 47:2554-2565 (1986).
Mulligan, M.S. et al., “Requirement and Role of C5a in Acute Lung Inflammatory Injury in Rats,”J. Clin. Invest. 98:503-512, 1996).
Nardelli et al., “A Chemically Defined Synthetic Vaccine Model for HIV-11,”J. Immunol. 148:914 (1992).
Nichols, “Classification of Surgical Wounds and Nonoperative Factors Influencing Surgical Wound Infection,”Decision Making in Surgical Sepsis, B.C. Decker, Inc., Philadelphia, pp. 20-21 (1991).
Nilsson et al., “Affinity Fusion Strategies for Detection, Purification, and Immobilization of Recombinant Proteins,”Prot. Expr. Purif., 11(1):1-16 [1997].
Olson et al., “The Role of C5 in Septic Lung Injury,”Ann. Surg. 202:771-776 (1985).
Park et al., “Attenuation of Endothelium-Dependent Dilation of Pig Pulmonary Arterioles After Cardiopulmonary Bypass is Prevented by Monoclonal Antibody to Complement C5a,”Anesth Anag89:42-9 (1999).
Posnett et al., “A Novel Method for Producing Anti-peptide Antibodies,”JBC263:1719 (1988).
Roberge et al., “A Strategy for a Convergent Synthesis of N-Linked Glycopeptides on a Solid Support,”Science269:202-204 (1995).
Rothermel et al. “Nucleotide and corrected amino acid sequence of the functional recombinant rat anaphylatoxin C5a1,”Biochim. Biophys. Acta1351 (1-2), 9-12, (1997).
Schlienger et al., “Human Immunodeficiency Virus Type 1 Major Neutralizing Determinant Exposed on Hepatitis B Surface Antigen Particles Is Highly Immunogenic in Primates,”J. Virol. 66:2 (1992).
Schulman et al., “Cost-effectiveness of HA-1A Monoclonal Antibody for Gram-Negative Sepsis,”JAMA266:3466-3471 (1991).
Slack and I.S. Snyder,Bacteria and Human Disease, pp. 128-133, Yearbook Medical Publishers (1978).
Solomkin, J.S., et al., “Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation,”Surgery90:319-327 (1981).
Stahel, et al., “TNF-α-Mediated Expression of the Receptor for Anaphylatoxin C5a on Neurons in ExperimentalListeriaM

Affiliated with

Also associated with

Rating

Compositions and methods for the treatment of sepsis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for the treatment of sepsis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment of sepsis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3541036